Intech Biopharm Statistics

Total Valuation

Intech Biopharm has a market cap or net worth of TWD 2.80 billion. The enterprise value is 4.11 billion.

Market Cap	2.80B
Enterprise Value	4.11B

Important Dates

The next estimated earnings date is Sunday, August 10, 2025.

Earnings Date	Aug 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Intech Biopharm has 137.94 million shares outstanding. The number of shares has increased by 9.42% in one year.

Current Share Class	137.94M
Shares Outstanding	137.94M
Shares Change (YoY)	+9.42%
Shares Change (QoQ)	+0.19%
Owned by Insiders (%)	1.21%
Owned by Institutions (%)	2.26%
Float	74.72M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	85.72
PB Ratio	3.85
P/TBV Ratio	3.86
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.77
EV / Sales	125.82
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.04

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 2.08.

Current Ratio	0.89
Quick Ratio	0.49
Debt / Equity	2.08
Debt / EBITDA	n/a
Debt / FCF	-4.08
Interest Coverage	-10.73

Financial Efficiency

Return on equity (ROE) is -41.87% and return on invested capital (ROIC) is -9.47%.

Return on Equity (ROE)	-41.87%
Return on Assets (ROA)	-9.03%
Return on Invested Capital (ROIC)	-9.47%
Return on Capital Employed (ROCE)	-19.09%
Revenue Per Employee	362,978
Profits Per Employee	-4.24M
Employee Count	90
Asset Turnover	0.01
Inventory Turnover	2.69

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.09% in the last 52 weeks. The beta is -0.12, so Intech Biopharm's price volatility has been lower than the market average.

Beta (5Y)	-0.12
52-Week Price Change	-25.09%
50-Day Moving Average	18.36
200-Day Moving Average	25.02
Relative Strength Index (RSI)	61.78
Average Volume (20 Days)	342,412

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Intech Biopharm had revenue of TWD 32.67 million and -381.66 million in losses. Loss per share was -2.78.

Revenue	32.67M
Gross Profit	-165.03M
Operating Income	-367.78M
Pretax Income	-381.66M
Net Income	-381.66M
EBITDA	-280.20M
EBIT	-367.78M
Loss Per Share	-2.78

Full Income Statement

Balance Sheet

The company has 207.19 million in cash and 1.52 billion in debt, giving a net cash position of -1.31 billion or -9.50 per share.

Cash & Cash Equivalents	207.19M
Total Debt	1.52B
Net Cash	-1.31B
Net Cash Per Share	-9.50
Equity (Book Value)	728.13M
Book Value Per Share	5.28
Working Capital	-48.37M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -320.64 million and capital expenditures -51.51 million, giving a free cash flow of -372.16 million.

Operating Cash Flow	-320.64M
Capital Expenditures	-51.51M
Free Cash Flow	-372.16M
FCF Per Share	-2.70

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,125.81%
Pretax Margin	-1,168.29%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Intech Biopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.42%
Shareholder Yield	n/a
Earnings Yield	-13.63%
FCF Yield	-13.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Intech Biopharm has an Altman Z-Score of 0.47 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.47
Piotroski F-Score	1